Why you soon won't be able to find Incannex shares on the ASX

This healthcare share plans to pack its bags and move to the US.

The days of Incannex Healthcare Ltd (ASX: IHL) shares trading on the ASX boards are now numbered.

That's because this morning, the cannabis-focused clinical-stage pharmaceutical development company has announced plans to redomicile from Australia to the United States.

This will be via proposed schemes of arrangement between Incannex and its shareholders and option holders, subject to their approval, as well as customary regulatory approvals.

Man sitting in a plane seat works on his laptop.

Image source: Getty Images

Why are Incannex shares leaving the ASX?

According to the release, the Incannex board believes that becoming a U.S. company and trading only on the NASDAQ will provide many and varied benefits to Incannex and its shareholders.

It believes that the company will have greater access to a more cognisant and receptive capital market of Incannex's value proposition. The board also highlights that comparison companies are trading at far greater market valuations and switching would provide it with the ability to expand to a much broader investor base.

Incannex CEO and Managing Director, Joel Latham, said:

The Board is excited to enact this landmark unanimous decision in conjunction with our key shareholders and other stakeholders. It is a decision made with the intention to maximise shareholder value.

Incannex has matured on the ASX to the point that it has a large and diversified drug portfolio with two exciting drug candidates imminently entering pivotal clinical trials. By committing our presence to the United States, we believe that our Company's visibility to international investors will increase markedly, partly due to our value proposition compared to similar emerging biotech companies with a presence in North America.

What's next?

The company expects to allow shareholders to vote on the proposal at a meeting in October.

If the proposal is approved, holders of Incannex shares will be entitled to receive one share of common stock in Incannex US for every 100 shares held on the record date for the share scheme. The value of the holding would remain the same at conversion.

Incannex shares are down 40% since this time last year.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Two doctors having a discussion about a patient diagnosis, holding digital tablet.
Healthcare Shares

The hunt for Australia's next CSL: 3 ASX healthcare shares with enormous potential

I look at three healthcare businesses that could be much larger companies in the years ahead.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Should I invest $2,000 into Mesoblast shares?

I look at whether commercial progress has made this long-awaited biotech story worth investing in today.

Read more »

Two colleagues looking at a graph and comparing share prices.
Healthcare Shares

Pro Medicus vs Telix Pharmaceuticals: Which is more likely to double your money in 2 years?

Can Pro Medicus or Telix Pharmaceuticals double your money on the ASX? We stack up their value, growth, and price…

Read more »

Happy doctor using her laptop.
Healthcare Shares

CSL has a new CEO. Are its shares a buy?

I look at what the incoming CEO could bring to the business as its recovery continues.

Read more »

Man holding a calculator with Australian dollar notes, symbolising dividends.
Healthcare Shares

Forget term deposits! I'd buy these ASX dividend shares instead

Term deposits are not exciting to me because of one key reason.

Read more »

A sobbing businessman accused of wrongdoing faces justice
Healthcare Shares

CSL responds to class action, defends disclosure record

The CSL share price is under the microscope after it revealed it will defend a newly filed class action lawsuit.

Read more »

Happy businessman fist pumping while looking at a tablet.
Healthcare Shares

Up 13%: Why is everyone buying Pro Medicus shares this week?

The ASX healthcare shares jumped another 3% on Wednesday.

Read more »

healthcare worker overseeing group of aged care residents at table
Healthcare Shares

Regis Healthcare vs Ryman Healthcare: Which under-the-radar ASX small-cap could double from here?

We compare Regis Healthcare and Ryman Healthcare shares to find out which aged care small-cap could bounce back faster.

Read more »